Home›Fentanyl Transdermal›Fentanyl Transdermal + Rifampin

Does Fentanyl Transdermal Interact with Rifampin?

CDI records a major classification for Fentanyl Transdermal and Rifampin. The stored summary is: CYP3A4 inducer; concomitant use can decrease plasma concentration of fentanyl, resulting in decreased efficacy or withdrawal syndrome. Stopping inducer may increase fentanyl levels causing serious respiratory depression. The mechanism involves cyp3a4 induction. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity
Major
Fentanyl Transdermal Class
Opioid Agonist
Rifampin Class
Rifamycin Antibacterial
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

CYP3A4 induction

What To Tell Your Doctor or Pharmacist

If you are taking Fentanyl Transdermal and your doctor is considering prescribing Rifampin (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Fentanyl Transdermal(Ionsys)+💊 Rifampin(Rifadin)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Opioid Agonist
Drug B class
Rifamycin Antibacterial
Source
NLP:fentanyl transdermal

What this means in plain English

CYP3A4 inducer; concomitant use can decrease plasma concentration of fentanyl, resulting in decreased efficacy or withdrawal syndrome. Stopping inducer may increase fentanyl levels causing serious respiratory depression.

About Fentanyl Transdermal and Rifampin

Fentanyl Transdermal is an Opioid Agonist, while Rifampin is a Rifamycin Antibacterial. You may recognize them by the brand names Ionsys and Rifadin. Fentanyl Transdermal additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:fentanyl transdermal

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Fentanyl Transdermal and Rifampin against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations